Company

Recreating human physiology in vitro for better therapies and disease research without animal experiments.

At Dynamic42, we aim to transform the way drug development and disease research is done. We build human microphysiological systems, to address critical points where pathogens and therapeutic compounds interact with humans. Leveraging our expertise in immune cell integration and perfusion, we aim to build organ models that can address the full complexity of research questions around human biology with a special focus on infection modelling.

Our commitment extends to improving drug development, reducing side effects, and minimizing the risk of translational failure. We want to help our partners to actively reduce animal experimentation, by offering advanced infection and disease models that surpass standard cell culture methods.

Dynamic42 aims to lead in establishing human, physiological organ models, contributing to ethical research practices, and fostering a future where scientific advancements benefit humanity while minimizing the impact on animals.

Ethical and sustainable research without the use of animal models to improve clinical outcomes and disease insights.

Our vision at Dynamic42 is to lead the way in the economical and sustainable development of pharmaceuticals and therapies. We are dedicated to distributing human, microphysiological systems integrated with the latest technologies, aiming to minimize or replace animal experimentation. Upholding ethical values and sustainability in research and development is fundamental to our principles.

Central to our identity is a commitment to the well-being of humans. We strive to enhance drug development and disease research by offering human organ-on-chip models with true physiological complexity. This approach not only increases the safety of newly developed drugs and therapies but also reduces the likelihood of translational failure. Our daily motivation is rooted in the continues development of new applications, as well as the improvement and technological expansion of our platform, to achieve these visionary goals.